TR201902137T4 - Plug arrangement for a drug delivery device. - Google Patents
Plug arrangement for a drug delivery device. Download PDFInfo
- Publication number
- TR201902137T4 TR201902137T4 TR2019/02137T TR201902137T TR201902137T4 TR 201902137 T4 TR201902137 T4 TR 201902137T4 TR 2019/02137 T TR2019/02137 T TR 2019/02137T TR 201902137 T TR201902137 T TR 201902137T TR 201902137 T4 TR201902137 T4 TR 201902137T4
- Authority
- TR
- Turkey
- Prior art keywords
- plug
- container
- arrangement
- drug delivery
- inner ring
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 20
- 239000000463 material Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 12
- 238000003032 molecular docking Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 9
- 230000007935 neutral effect Effects 0.000 claims description 5
- 230000008602 contraction Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- 241000237970 Conus <genus> Species 0.000 claims 5
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 16
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108010011459 Exenatide Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229960001519 exenatide Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- -1 Gly(A21) Chemical class 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
- A61M5/31515—Connection of piston with piston rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/10—General characteristics of the apparatus with powered movement mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31501—Means for blocking or restricting the movement of the rod or piston
Abstract
Buluş, bir ilaç dağıtım cihazına (1) yönelik, bir tapa (5), bir ucu ile tapaya (5) ve karşıt bir ucu ile bir kenetlenme düzenlemesine (8) bağlı bir lineer aktör (7) içeren bir tapa düzenlemesi ile ilgilidir, burada tapa düzenlemesi, bir ilaç dağıtım cihazının (1) bir konteyneri (2) içinde düzenlenecek şekilde konfigüre edilir, burada tapa (5) ve kenetlenme düzenlemesinin (8) bir şekli ve/veya materyali, kenetlenme düzenlemesi (8) ile konteyner (2) arasındaki bir birinci sürtünme kuvvetinin, lineer aktör (7) daralırken tapa (5) ile konteyner (2) arasındaki bir sürtünme kuvvetinden daha düşük olacağı ve kenetlenme düzenlemesi (8) ile konteyner (2) arasındaki ikinci sürtünme kuvvetinin, lineer aktör (7) genişlerken tapa (5) ile konteyner (2) arasındaki sürtünme kuvvetinden daha büyük olacağı şekilde konfigüre edilir.The invention relates to a plug arrangement for a drug delivery device (1), comprising a plug (5), a linear actuator (7) connected to the plug (5) with one end and a clamping arrangement (8) with an opposite end, here The plug arrangement is configured to be arranged in a container (2) of a drug delivery device (1), where the plug (5) and a form and / or material of the interlocking arrangement (8) are between the interlocking arrangement (8) and the container (2). a first friction force will be lower than a friction force between the plug (5) and the container (2) as the linear actuator (7) contracts, and the second friction force between the clamping arrangement (8) and the container (2) as the linear actuator (7) expands It is configured so that it is greater than the friction force between (5) and the container (2).
Description
TARIFNAME BIR ILAÇ DAGITIM CIHAZINA YÖNELIK TAPA DÜZENLEMESI Teknik Saha Bulus, bir ilaç dagitim cihazina yönelik bir tapa düzenlemesi ile ilgilidir. DESCRIPTION PLUG ARRANGEMENT FOR A MEDICINE DISPENSER Technical Field The invention relates to a plug arrangement for a drug delivery device.
Bulusun Alt Yapisi Klasik ilaç dagitim cihazlari, içerisinde bir ilacin muhafaza edilmesine yönelik bir bosluk tanimlayan bir konteyner, konteynerin bir distal ucunda düzenlenen bir nozül, örnegin bir enjeksiyon ignesi ve ilacin yerinden çikarilmasina yönelik olarak, konteyner içinde düzenlenen bir pistonlu bir tapa içerir, burada nozül, bosluk ile akiskan madde iletisimi içindedir. çubuguna baglanmasi Için adapte edilen bir tapa açiklar. Tapa, açik bir arka uç ve kapali bir ön uç tanimlayan bir ana gövde içerir. Açik arka uç, piston çubugunun öndeki bir ileri bakan uç baglanti parçasini alacak sekilde adapte edilir. Tapa ayni zamanda, söz konusu ana gövde ile tümlesik olarak olusturulan, kapali ön uca bitisik bir göbek elemani içerir. Göbek elemani, bu tür bir siringa haznesinin bir çikis açikligina karsi tam sizdirmazlik olusturacak sekilde adapte edilen bir profile sahip bir burun parçasi Bulusun Kisa Açiklamasi Mevcut bulusun bir amaci, gelistirilmis bir tapa düzenlemesinin saglanmasidir. Background of the Invention Conventional drug delivery devices have a cavity in which a drug is contained. defining a container, a nozzle arranged at a distal end of the container, e.g. an injection needle and for drug removal, in a container includes a plug with an arranged piston, wherein the nozzle communicates with the cavity and the fluid is in it. Describes a plug adapted to connect to the bar. The plug is an open backend and includes a main body that defines a closed front end. Open rear end, front of piston rod it is adapted to receive a forward facing end fitting. The plug is also a hub adjacent to the closed front end, integrally formed with said main body contains the element. The core member is opposed to an outlet opening of such a syringe barrel. a nose piece with a profile adapted to create a complete seal Brief Description of the Invention It is an object of the present invention to provide an improved plug arrangement.
Amaç, istem 1'e göre bir tapa düzenlemesi ile elde edilir. The object is achieved by a plug arrangement according to claim 1.
Bulusun tercih edilen düzenlemeleri, bagimli istemlerde verilir. Preferred embodiments of the invention are given in the dependent claims.
Bulusa göre, bir ilaç dagitim cihazina yönelik bir tapa düzenlemesi, bir tapa, bir ucu ile tapaya ve zit bir ucu ile bir kenetlenme düzenlemesine bagli bir lineer aktör içerir, burada tapa düzenlemesi, bir ilaç dagitim cihazinin bir konteyneri içerisinde düzenlenebilecek sekilde konfigüre edilir, burada tapa ve kenetlenme düzenlemesinin sekli ve/veya materyali, kenetlenme düzenlemesi ile konteyner arasindaki bir birinci sürtünme kuvvetinin, lineer aktör daralirken tapa ile konteyner arasindaki bir sürtünme kuvvetinden daha düsük olacagi ve kenetlenme düzenlemesi ile konteyner arasindaki ikinci sürtünme kuvvetinin, lineer aktör genislerken tapa ile konteyner arasindaki sürtünme kuvvetinden daha büyük olacagi sekilde konfigüre edilir. According to the invention, a plug arrangement for a drug delivery device consists of a plug with one end. includes a linear actor connected to the plug and an interlock arrangement with an opposite end, wherein the plug arrangement is contained within a container of a drug delivery device. configured to be editable, where the plug and interlock arrangement Its shape and/or material is a first between the docking arrangement and the container. friction force between the plug and the container as the linear actor contracts will be lower than the force and the interlocking arrangement between the container and the the second friction force between the plug and the container as the linear actor expands. It is configured to be greater than the frictional force.
Bulusa göre tapa düzenlemesi, kendinden tahriklidir, böylelikle bir piston kulbu gerekli olmadigindan, ilaç dagitim cihazlarinda büyük ölçüde azaltilmis bir toplam uzunluk Tapanin toplam ayar araliginin, lineer aktör ve kenetlenme düzenlemesinin açiklanan düzenlemesi yoluyla istege göre bir sayida küçük asamalara bölünebilmesi nedeniyle, lineer aktör, küçük bir ayar araligina sahip yüksek hassasiyetli bir lineer aktör olabilir. The plug arrangement according to the invention is self-actuating so that a piston rod is required. a greatly reduced overall length in drug delivery devices Description of the total adjustment range of the plug, linear actor and interlock arrangement. Since it can be arbitrarily divided into a number of smaller stages by means of The linear actor can be a high precision linear actor with a small adjustment range.
Bulusa göre, kenetlenme düzenlemesi, bir distal yöne dogru koniklesen en az bir kama blogu ve bir proksimal yöne dogru koniklesen bir konik iç halka içerir, burada kama blogu, iç halka ve konteyner arasinda düzenlenir, burada iç halka, proksimal olarak bir proksimal levhaya ve distal olarak lineer aktöre bitistirilir, burada kenetlenme düzenlemesi, iç halkanin, en az bir kama bloguna karsi sikistirilmadigi durumda, birinci sürtünme kuvveti ile konteynere baglanacak sekilde konfigüre edilir. Lineer aktör genislerken, iç halka, konteynere baglanmakta olan en az bir kama bloguna karsi sikistirilir, böylelikle ikinci sürtünme kuvvetine yönelik olarak sürtünme miktarini arttirir. According to the invention, the clamping arrangement consists of at least one wedge tapering in a distal direction. block and a conical inner ring tapering in a proximal direction, where the wedge The block is arranged between the inner ring and the container, where the inner ring is proximally a it is attached proximal to the plate and distally to the linear actor, where the docking 1st arrangement, where the inner ring is not compressed against at least one wedge block. It is configured to be connected to the container by friction force. linear actor as it expands, the inner ring opposes at least one wedge block connecting to the container. is compressed, thereby increasing the amount of friction for the second friction force.
Kenetlenme düzenlemesi lineer aktörün daralmasi üzerine tapaya dogru çekildiginde, birinci sürtünme kuvveti, kama bloklari ile iç konteyner duvari arasindaki kuweti içerir. When the clamping arrangement is pulled towards the plug upon contraction of the linear actor, The first frictional force includes the force between the wedge blocks and the inner container wall.
Birinci sürtünme kuvveti ayni zamanda, konteyner ile temas içinde olabilen proksimal levhanin bir sürtünme bilesenini içerebilir. Bu, en azindan zaman zaman, kenetlenme düzenlemesinin konteyner içerisindeki hareketi sirasinda meydana gelebilir. The first friction force is also the proximal force that may be in contact with the container. the plate may include a friction component. This is, at least at times, docking. may occur during the movement of the arrangement in the container.
Tapanin, konteyner içindeki sürtünme kuvveti, birinci sürtünme kuweti ile birlikte, kenetlenme mekanizmasinin serbest birakilmasina yönelik gerekli olan kuwetten daha büyük olacak sekilde konfigüre edilir. Ancak tapanin, konteyner içindeki sürtünme kuvveti ayni zamanda, lineer aktör genislerken, kenetlenme mekanizmasinin ikinci sürtünme kuvvetinden daha küçük olacak sekilde konfigüre edilir. Örnek niteligindeki bir düzenlemede, iç halka, bir konüs ile degistirilebilir. Ancak iç halka, azaltilmis bir uzunluk saglar. Örnek niteligindeki bir düzenlemede, kama blogu, distal yönde, ilgili bir yönlendirme elemani, örnegin bir sikistirma yayi olarak düzenlenmis bir yay yoluyla proksimal kancalar yoluyla proksimal Ievhadan mesafeli tutulabilir. Alternatif bir düzenlemede, iç halkanin yüzeyi üzerindeki çentikler veya iç halkanin proksimal ucundan uzanan kancalar, kama blogu tutacak sekilde konfigüre edilebilir. Böylelikle, bir proksimal levha gerekli olmaz. Örnek niteligindeki bir düzenlemede, lineer aktör, bir solenoid içerir. The friction force of the plug inside the container, together with the first friction force, greater than the force required to release the clamping mechanism. configured to be large. However, the plug is caused by friction within the container. force of the interlocking mechanism also increases as the linear actor expands. It is configured to be smaller than the friction force. In an exemplary embodiment, the inner ring may be replaced by a cone. But inside the ring provides a reduced length. In an exemplary embodiment, the wedge block has a corresponding orientation in the distal direction. element proximal through a spring arranged, for example, as a compression spring. can be kept at a distance from the proximal plate by means of hooks. In an alternative embodiment, the internal notches on the surface of the ring or extending from the proximal end of the inner ring hooks can be configured to hold the wedge block. Thus, a proximal plate not necessary. In an exemplary embodiment, the linear actor includes a solenoid.
Bir diger örnek niteligindeki düzenlemede, lineer aktör, bir aks ve bir somuna sahip bir elektrik motoru içerir. Örnek niteligindeki bir düzenlemede, bir tapa levhasi, tapaya proksimal olarak bitistirilir ve lineer aktör, tapa Ievhasina bitistirilir. Tapa levhasi, tapaya serbest birakilabilir sekilde bitistirilir, bu sekilde tapa düzenlemesi, konteynerden çikarilabilir. Böylelikle, tapa düzenlemesi, konteyner atildiginda yeniden kullanilabilir, bu sekilde atik miktari ve çevresel etki azaltilir. In another exemplary embodiment, the linear actor is a drive with an axle and a nut. Includes electric motor. In an exemplary embodiment, a plug plate is attached proximally to the plug and the linear actor is attached to the plug plate. Plug plate can be released to plug so that the plug arrangement can be removed from the container. Thus, The plug arrangement can be reused when the container is discarded, thus reducing the amount of waste and environmental impact is reduced.
Lineer aktörün kontrol edilmesine yönelik bir enerji tedarik kablosu, proksimal levha ve iç halka içinden ilerletilebilir. Lineer aktör, benzer sekilde, tapa düzenlemesi içinde düzenlenen bir pil ile çalistirilabilir. Örnek niteligindeki bir düzenlemede, en az iki kama blogu, iç halka etrafinda es merkezli olarak düzenlenir. A power supply cable, proximal plate and can be advanced through the inner ring. Linear actor, similarly, in plug arrangement can be operated with a regulated battery. In an exemplary embodiment, at least two wedge blocks are synchronous around the inner ring. organized on a centered basis.
Tapa düzenlemesi, bir ilacin muhafaza edilmesine yönelik bir bosluk tanimlayan bir konteyner, konteynerin bir distal ucunda düzenlenen bir nozül içeren bir ilaç dagitim cihazi içinde kullanilabilir, burada nozül, bosluk ile akiskan madde iletisimi içindedir, burada tapa düzenlemesi, konteyner içinde düzenlenir. Örnek niteligindeki bir düzenlemede, kama blogunun veya kama bloklarinin, proksimal levhaya dogru bir nötr pozisyona hareket ettirilmesine yönelik bir uzaklastirma destegi düzenlenebilir. Lineer aktör ve kenetlenme düzenlemesini yeniden kullanmak amaciyla, bunlarin, konteynerin proksimal ucunun disina çekilmesi zorunludur. Bu amaca yönelik olarak, kama bloklari, yaylarin meyline karsi proksimal levhaya dogru nötr pozisyona hareket ettirilir, bu sekilde, proksimal levha ve iç halka proksimal yönde çekildiklerinde konteyner duvarini zorlamazlar. Örnek niteligindeki bir düzenlemede, uzaklastirma destegi, konteyner üzerinde disaridan düzenlenebilen bir halka miknatis içerir. The plug arrangement is a device that defines a space to contain a drug. The container is a drug delivery device comprising a nozzle arranged at a distal end of the container. can be used in the device, where the nozzle is in communication with the cavity of the fluid, wherein the plug arrangement is arranged in the container. In an exemplary embodiment, the wedge block or wedge blocks are a removal aid for moving it to a neutral position towards the plate editable. To reuse the linear actor and docking arrangement, they must be pulled out of the proximal end of the container. for this purpose As a result, the wedge blocks are placed in neutral position towards the proximal plate against the inclination of the springs. is moved, in this way, when the proximal plate and inner ring are pulled in the proximal direction. they do not force the container wall. In an exemplary embodiment, the removal support is mounted on the container. includes an externally adjustable ring magnet.
Bir diger örnek niteligindeki düzenlemede, uzaklastirma destegi, iç halka üzerinde veya proksimal levha üzerinde düzenlenen en az bir solenoid içerir. In another exemplary embodiment, the removal support is mounted on the inner ring or includes at least one solenoid arranged on the proximal plate.
Bir diger örnek niteligindeki düzenlemede, uzaklastirma destegi, konteynerin bir proksimal ucu içinden yerlestirilebilen bir mekanik veya manyetik alet içerir. In another exemplary embodiment, the removal support is part of the container. It contains a mechanical or magnetic device that can be inserted through its proximal end.
Tipik olarak konteyner ve tapa, silindirik bir enine kesite sahiptir. Ancak prizma, dikdörtgen, kare veya eliptik veya benzeri gibi farkli enine kesitler de mümkündür. Typically, the container and plug have a cylindrical cross-section. However, the prism Different cross-sections are also possible, such as rectangular, square or elliptical or the like.
Burada kullanilan "ilaç" veya "ilaç maddesi" terimi, en az bir farmasötik olarak aktif bilesik içeren farmasötik bir formülasyon anlamina gelir, burada bir düzenlemede, farmasötik olarak aktif bilesik, 1500 Da'ya kadar bir moleküler agirliga sahiptir ve/veya bir peptit, bir protein, bir polisakkarit, bir asi, bir DNA, bir RNA, bir enzim, bir antikor veya bunun bir fragmani, bir hormon veya bir oligonükleotid veya yukarida bahsedilen farmasötik olarak aktif bilesigin bir karisimidir, burada bir baska düzenlemede, farmasötik olarak aktif bilesik diabetes mellitusun veya diabetik retinopati gibi diabetes mellitus ile iliskili komplikasyonlarin, derin ven veya pulmoner tromboembolizm gibi tromboembolizm bozukluklarinin, akut koroner sendrom (ACS), anjina, miyokard enfarktüsü, kanser, maküla dejenerasyonu, inflamasyon, saman nezlesi, ateroskleroz ve/veya romatoid artritin tedavisi ve/veya profilaksisi için faydalidir, burada bir baska düzenlemede, farmasötik olarak aktif bilesik, diabetes mellitusun veya diabetik retinopati gibi diabetes mellitus ile iliskili komplikasyonlarin tedavisi ve/veya profilaksisi için en az bir peptit içerir, burada bir baska düzenlemede, farmasötik olarak aktif bilesik, en az bir insan insülini veya bir insan insülin analogu veya türevi, glukagon benzeri peptit (GLP-1 ) veya bunun bir analogu veya türevi veya eksedin-3 veya eksedin-4 veya eksedin-3 veya eksedin- 4lün bir analogu veya türevini içerir. As used herein, the term "drug" or "pharmaceutical substance" refers to at least one pharmaceutically active means a pharmaceutical formulation containing a compound, wherein in one embodiment, the pharmaceutically active compound has a molecular weight of up to 1500 Da. weight and/or a peptide, a protein, a polysaccharide, an acid, a DNA, an RNA, an enzyme, an antibody or fragment thereof, a hormone or an oligonucleotide, or is a mixture of the pharmaceutically active compound mentioned above, wherein in another embodiment, the pharmaceutically active compound is used to treat diabetes mellitus or complications associated with diabetes mellitus, such as diabetic retinopathy, deep vein or thromboembolism disorders such as pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, for the treatment and/or prophylaxis of hay fever, atherosclerosis and/or rheumatoid arthritis it is useful, wherein in another embodiment, the pharmaceutically active compound is used to treat diabetes mellitus or treatment of complications associated with diabetes mellitus, such as diabetic retinopathy, and/or Contains at least one peptide for prophylaxis, wherein in another embodiment, the pharmaceutically active compound is at least one human insulin. or a human insulin analog or derivative, glucagon-like peptide (GLP-1 ) or its an analogue or derivative or exedin-3 or exedin-4 or exedin-3 or exedin- Contains an analog or derivative of 4.
Insülin analoglari örnegin Gly(A21), Arg(B31), Arg(832) insan insülini; Lys(BS), insan insülinidir, burada 828 konumundaki prolin, Asp, Lys, Leu, Val veya Ala ile yer degistirilir ve burada insan insülini; Des( insan insülini ile yer degistirilebilir. Insulin analogs such as Gly(A21), Arg(B31), Arg(832) human insulin; Lys(BS), is human insulin, where proline at position 828 replaces Asp, Lys, Leu, Val or Ala changed and here human insulin; Des( can be replaced by human insulin.
Insülin türevleri örnegin, BZQ-N-miristoiI-des(BSO) insan insülini; B29-N-palmitoil- des(830) insan insülini; BZQ-N-miristoil insan insülini; BZQ-N-palmitoil insan insülini; BZß-N-miristoil LysBZSProBZQ insan insülini; BZS-N-palmitoiI-LysBZ8ProBZQ insan insülini; BßO-N-miristoiI-ThrB29LysBSO insan insülini; BßO-N-palmitoiI-ThrB29LysBSO insan insülini; B29-N-(N-paImitoil-Y-gIutamiI)-des(BSO) insan insülini; B29-N-(N-lit0k0lil- Y-glutamiI)-des( insan insülini ve BZQ-N-(w-karboksiheptadekanoil) insan insülinidir. Insulin derivatives such as BZQ-N-myristoyl-des(BSO) human insulin; B29-N-palmitoyl- des(830) human insulin; BZQ-N-myristoyl human insulin; BZQ-N-palmitoyl human insulin; BZß-N-myristoil LysBZSProBZQ human insulin; BZS-N-palmitoii-LysBZ8ProBZQ human insulin; BßO-N-myristoyl-ThrB29LysBSO human insulin; BßO-N-palmitoii-ThrB29LysBSO human insulin; B29-N-(N-paImitoyl-Y-glutamil)-des(BSO) human insulin; B29-N-(N-lit0k0lil- Y-glutamyl)-des( human insulin and BZQ-N-(w-carboxyheptadecanoyl) human insulin.
Eksendin-4 örnegin H-His-Gly-GIu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn-Met-GIu- GIu-Glu-Ala-VaI-Arg-Leu-Phe-Ile-GIu-Trp-Leu-Lys-Asn-GIy-GIy-Pro-Ser-Ser-GIy-Ala- Pro-Pro-Pro-Ser-NHZ dizisinin bir peptidi olan Eksendin-4(1-39) anlamina gelir. Exendin-4 eg H-His-Gly-GIu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-GIn-Met-GIu- GIu-Glu-Ala-VaI-Arg-Leu-Phe-Ile-GIu-Trp-Leu-Lys-Asn-GIy-GIy-Pro-Ser-Ser-GIy-Ala- It stands for Exendin-4(1-39), a peptide of the sequence Pro-Pro-Pro-Ser-NHZ.
Eksendin-4 türevleri örnegin, bilesiklerin asagidaki listesinden seçilir: des Pro36 Eksendin-4(1-39), des Pro36 [lsoAsp28] Eksendin-4(1-39), des Pr; veya burada -Lysß-NH2 grubu, Eksendin-4 türevinin C-terminaline; veya asagidaki dizinin bir Eksendin-4 türevine H-(Lys)6-des Pr-Lysö-NH2, H-Asn-(Glu)5des Pr036, Pr037, Pr-NH2, des Pr036, Pr037, Pr6-NH2, H-Asn-(GIu)5-des Pr036, Pr037, Pr6-NH2, H-(Lys)6-des Pr-LysG-NH2, H-des Asp28 Pr036, Pro37, Pr-NH2, H-Asn-(GIu)5-des Pr036, Pr037, Pr-NH2, des Pr036, Pr037, Pr6-NH2, H-(Lys)6-des Pr-Lysö-NH2, H-Asn-(GIu)5-des Pr036, Pr037, Pr-NH2, des Pr036, Pr037, Pr6-NH2, H-(Lys)6-des Pr036, Pro37, Pr6-NH2. Exendin-4 derivatives, for example, are selected from the following list of compounds: des Pro36 Exendin-4(1-39), des Pro36 [lsoAsp28] Exendin-4(1-39), des Pr; or where the -Lysß-NH2 group is attached to the C-terminus of the Exendin-4 derivative; or to an Axiend-4 derivative of the following sequence H-(Lys)6-des Pr-Lyso-NH2, H-Asn-(Glu)5des Pr036, Pr037, Pr-NH2, des Pr036, Pr037, Pr6-NH2, H-Asn-(GIu)5-des Pr036, Pr037, Pr6-NH2, H-(Lys)6-des Pr-LysG-NH2, H-des Asp28 Pr036, Pro37, Pr-NH2, H-Asn-(GIu)5-des Pr036, Pr037, Pr-NH2, des Pr036, Pr037, Pr6-NH2, H-(Lys)6-des Pr-Lyso-NH2, H-Asn-(GIu)5-des Pr036, Pr037, Pr-NH2, des Pr036, Pr037, Pr6-NH2, H-(Lys)6-des Pr036, Pro37, Pr6-NH2.
H-Asn-(Glu)5 des Pr036, Pr037, Pr6- H-LysG-des Pr-LysG-NH2, 39)-NH2, des Pr036, Pr037, Pr6-NH2, 39)-(Lys)6-NH2; veya yukarida bahsedilen Eksendin-4 türevinden herhangi birinin farmasötik olarak kabul edilebilir bir tuzu veya solvatina baglanabilir. H-Asn-(Glu)5 des Pr036, Pr037, Pr6- H-LysG-des Pr-LysG-NH2, 39)-NH2, des Pr036, Pr037, Pr6-NH2, 39)-(Lys)6-NH2; or any of the aforementioned Exendin-4 derivatives as pharmaceuticals may bind to an acceptable salt or solvatin.
Hormonlar örnegin, hipofiz hormonlari veya hipotalamus hormonlari veya düzenleyici aktif peptitler ve Gonadotropin (Follitropin, Lutropin, Koriongonadotropin, Menotropin), Somatropin (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Löprorelin, Buserelin, Nafarelin, Goserelin gibi Rote Liste, ed. 2008, Chapter 50'de Bir polisakkarit örnegin bir glukozaminoglikan, bir hiyalüronik asit, bir heparin, düsük moleküler agirlikli bir heparin veya ultra düsük agirlikli bir heparin veya bunun bir türevi veya yukarida bahsedilen polisakkaritlerin sülfatli, örnegin poIi-sülfatli bir formu ve/veya bunun farmasötik olarak kabul edilebilir bir tuzudur. Bir poIi-sülfaltlanmis düsük moleküler agirlikli heparinin farmasötik olarak kabul edilen bir tuzunun bir örnegi, enoksaparin sodyumdur. Hormones, for example, pituitary hormones or hypothalamus hormones or regulatory active peptides and Gonadotropin (Follitropin, Lutropin, Choriogonadotropin, Menotropin), Somatropin (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Rote Liste, ed., such as Loprorelin, Buserelin, Nafarelin, Goserelin. 2008 at Chapter 50 A polysaccharide such as a glucosaminoglycan, a hyaluronic acid, a heparin, a low a molecular weight heparin or an ultra-low weight heparin or a derivative thereof or a sulfated, eg poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. A poly-sulphated lower an example of a pharmaceutically acceptable salt of molecular weight heparin, enoxaparin sodium.
Antikorlar. bazik bir yapiyi paylasan immünoglobulinler olarak da bilinen globüler plazma proteinleridir (~. Amino asit kalintilarina eklenen seker zincirleri oldugundan, bunlar glikoproteinlerdir. Her antikorun bazik islevsel birimi bir immünoglobulin (lg) monomeridir (sadece bir lg birimi içerir); salgilanan antikorlar ayrica IgA'da oldugu gibi iki lg birimi ile dimerik, teleost balik lgM gibi dört lg birimi olan tetramerik veya memeli IgM'si gibi bes lg birimi ile pentamerik olabilir. lg monomeri, dört polipeptit zincirinden olusan "Y" seklinde bir moleküldür; iki özdes agir zincir ve sistein kalintilari arasindaki disülfid baglari ile birbirine baglanmis iki özdes hafif zincirdir. Her agir zincir yaklasik 440 amino asit uzunlugundadir; her hafif zincir yaklasik 220 amino asit uzunlugundadir. Agir ve hafif zincirlerin her biri, katlanmalarini stabilize eden zincir-içi disülfid baglari içerir. Her zincir lg domenleri olarak adlandirilan yapisal domenlerden olusur. Bu domenler yaklasik 70-110 amino asit içerir ve boyutlarina ve islevlerine göre farkli kategorilere (örnegin degisken veya V ve sabit veya C) siniflandirilir. Bunlar, iki [3 tabakanin, korunmus sisteinler ve diger yüklü amino asitler arasindaki etkilesimlerle bir arada tutulan bir "sandviç" sekli olusturdugu karakteristik bir immünoglobulin katina sahiptir. a, 6, 8, v ve u ile gösterilen bes tip memeli lg agir zinciri vardir. Mevcut agir zincirin tipi, antikorun izotipini tanimlar; bu zincirler sirasiyla IgA, IgD, IgE, IgG ve lgM antikorlarinda bulunur. antibodies. globular, also known as immunoglobulins that share a basic structure are plasma proteins (~. sugar chains added to amino acid residues Because they are glycoproteins. The basic functional unit of each antibody is a is an immunoglobulin (lg) monomer (contains only one lg unit); secreted antibodies It also has two lg units as in IgA and four lg units such as dimeric, teleost fish lgM. it may be tetrameric or pentameric with five lg units such as mammalian IgM. The Ig monomer is a "Y" shaped molecule composed of four polypeptide chains; two identical two interconnected by disulfide bonds between the heavy chain and cysteine residues. identical light chain. Each heavy chain is approximately 440 amino acids long; every light The chain is approximately 220 amino acids long. Each of the heavy and light chains contains intra-chain disulfide bonds that stabilize their folding. Each chain lg domains It consists of structural domains called These domains are approximately 70-110 amino acids. contains acids and is classified into different categories (e.g. variable or V) according to their size and function. and are classified as fixed or C). These are the two [3 layers, conserved cysteines and other a "sandwich" shape held together by interactions between charged amino acids It has a characteristic immunoglobulin layer that it forms. There are five types of mammalian igneous chains, designated a, 6, 8, v, and u. Type of existing heavy chain, identify the isotype of the antibody; these chains are IgA, IgD, IgE, IgG and IgM, respectively. found in antibodies.
Farkli agir zincirler boyut ve bilesim bakimindan degisiklik gösterir; u ve e yaklasik olarak 550 amino aside sahipken, o ve y yaklasik olarak 450 amino asit ve 6 yaklasik olarak 500 amino asit içerir. Her bir agir zincir iki bölgeye, sabit bölge (CH) ve degisken bölge (VH) sahiptir. Bazi türlerde, sabit bölge ayni izotipin bütün antikorlarinda temelde özdestir ancak farkli izotiplerin antikorlarinda degiskenlik gösterir. Agir zincirler (y, oi ve 6), ardisik üç lg domeninden olusan sabit bir bölgeye ve eklenen esneklige yönelik bir mentese bölgesine sahiptir; agir zincirler (u ve 5), dört immunoglobülin domeninden olusan sabit bir bölgeye sahiptir. Agir zincirlerin degisken bölgesi, farkli B hücrelerinden üretilen antikorlarda degiskenlik gösterir ancak tek bir B hücresi veya B hücre klonu araciligiyla üretilen bütün antikorlara yönelik aynidir. Her bir agir zincirin degisken bölgesi, yaklasik olarak 110 amino asit uzunlugundadir ve tek bir lg domeninden Memelilerde A ve K ile ifade edilen iki tip immunoglobülin hafif zinciri vardir. Bir hafif zincir iki ardisik domene sahiptir: bir sabit domen (CL) ve bir degisken domen (VL). Bir hafif zincirin yaklasik uzunlugu, 211 ila 217 amino asittir. Her bir antikor, her zaman özdes olan iki hafif zincir içerir; hafif zincirlerin sadece tek tipi (K veya )\), memelilerde antikor basina mevcuttur. Different heavy chains vary in size and composition; u and e are about It has 550 amino acids, while o and y are approximately 450 amino acids and 6 are approximately It contains 500 amino acids. Each heavy chain has two regions, the constant region (CH) and the variable region. region (VH). In some species, the constant region is essentially found in all antibodies of the same isotype. are identical but vary in antibodies of different isotypes. Heavy chains (y, oi and 6) a fixed region of three consecutive IG domains and a framework for added flexibility. it has a hinge region; heavy chains (u and 5) are from the four immunoglobulin domains It has a fixed region. Variable region of heavy chains from different B cells varies in antibodies produced, but a single B cell or B cell clone is the same for all antibodies produced through Variable of each heavy chain region is approximately 110 amino acids long and is derived from a single Ig domain. There are two types of immunoglobulin light chains in mammals, expressed as A and K. a light The chain has two consecutive domains: a constant domain (CL) and a variable domain (VL). A The approximate length of the light chain is 211 to 217 amino acids. Each antibody is always contains two identical light chains; only one type of light chain (K or )\), in mammals available per antibody.
Bütün antikorlarin genel yapilari oldukça benzer olmasina ragmen, belirli bir antikorun essiz özelligi, yukarida detaylandirildigi üzere degisken (V) bölgeler ile belirlenir. Daha spesifik olarak, her bir üçü hafif (VL) ve üçü agir (VH) zincirdeki degisken döngüler, antijene baglanmaktan diger bir deyisle antijen spesifikliginden sorumludur. Bu döngüler, Tamamlayici Belirleme Bölgeleri (CDR'Ier) olarak refere edilir. VH ve VL domenlerinden olusan CDR'Ier, antijen-baglayan alana katki saglamasi nedeniyle, agir ve hafif zincirlerin bir kombinasyonudur ve tek basina degildir, bu, nihai antijen spesifikligini belirler. Although the general structures of all antibodies are quite similar, a particular antibody Its unique feature is determined by variable (V) regions as detailed above. More specifically, alternating loops in each of the three light (VL) and three heavy (VH) chains, It is responsible for binding to antigen, in other words for antigen specificity. This loops are referred to as Complementary Detection Regions (CDRs). VH and VL CDRs consisting of domains are heavy, as they contribute to the antigen-binding domain. and light chains and not alone, this is the final antigen determines its specificity.
Bir “antikor fragmani”, yukarida tanimlandigi üzere en az bir antijen baglayici fragmanini içerir ve temelde fragmanin türetildigi tam antikor ile ayni islevi ve spesifikligi gösterir. Papain ile sinirli proteolitik sindirim lg prototipini üç fragmana klevaj eder. Her biri bütün bir L zinciri ve yaklasik yarim bir H zinciri içeren iki özdes amino terminal fragmani, antijen baglayici parçalardir (Fab). Boyut olarak benzer olan ancak zincirler arasi disülfid bagi ile her iki agir zincirin karboksil terminal yarisini içeren üçüncü fragman, kristallesebilir fragmandir (FC). Fc, karbonhidratlar, tamamlayici baglama ve PCR-baglayici alanlari içerir. Sinirli pepsin sindirimi, H-H zincirler arasi disülfid bagi da kapsayarak, Fab parçalarini ve mentese bölgesini içeren tek bir F(ab')2 fragmanini saglar. F(ab')2, antijen baglanmasina yönelik divalenttir. F(ab')2'nin disülfid bagi, Fab' elde etmek amaciyla klevaj edilebilir. Ayrica agir ve hafif zincirlerin degisken bölgeleri, tek bir zincir degisken fragmani (scFv) olusturmak üzere kaynastirilabilir. An "antibody fragment" means at least one antigen-binding, as defined above. contains the fragment and essentially has the same function and function as the full antibody from which the fragment is derived. shows specificity. Cleavage the Ig prototype into three fragments of proteolytic digestion restricted with papain it does. Two identical amino acids, each containing an entire L chain and about half an H chain. the terminal fragment is the antigen-binding fragments (Fab). similar in size but containing the carboxyl terminal half of both heavy chains with an interchain disulfide bond. the third fragment is the crystallizable fragment (FC). Fc, carbohydrates, supplement contains binding and PCR-binding domains. Restricted pepsin digestion, H-H interchain A single F(ab')2 containing Fab fragments and hinge region, including disulfide bond provides the fragment. F(ab')2 is divalent for antigen binding. disulfide of F(ab')2 The ligand can be cleaved to obtain Fab'. In addition, the heavy and light chains regions can be fused to form a single chain variable fragment (scFv).
Farmasötik olarak kabul edilebilir tuzlar örnegin ilave asit tuzlari ve bazik tuzlardir. Ilave asit tuzlari örnegin HCI veya HBr tuzlaridir. Bazik tuzlar örnegin, alkali veya alkalinden seçilen bir katyon, örnegin Na+ veya K+ veya Ca2+ veya bir amonyum iyonu N+(R1)(R2)(R3)(R4),e sahip tuzlardir, burada R1 ila R4 birbirlerinden bagimsiz olarak: hidrojen, istege bagli olarak sübstitüe edilmis C1-Cö-alkil grubu, istege bagli olarak sübstitüe edilmis bir CZ-Cö-alkenil grubu, istege bagli olarak sübstitüte edilmis bir Cö- C10-aril grubu veya istege bagli olarak sübstitüe edilmis bir Cö-C10-heteroaril grubu anlamina gelir. Farmasötik olarak kabul edilebilir tuzlarin diger örnekleri, "Remington's Pharmaceutical Sciences" 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 ve Encyclopedia of Pharmaceutical Technology içinde açiklanir. Pharmaceutically acceptable salts are, for example, addition acid salts and basic salts. Additional acid salts are, for example, HCl or HBr salts. Basic salts eg alkali or alkaline a selected cation, for example Na+ or K+ or Ca2+ or an ammonium ion are salts with N+(R1)(R2)(R3)(R4), where R1 to R4 independently of each other are: hydrogen, optionally substituted C1-C6-alkyl group, optionally a substituted CZ-C6-alkenyl group, an optionally substituted C6-alkenyl group C10-aryl group or an optionally substituted C6-C10-heteroaryl group It means. Other examples of pharmaceutically acceptable salts are "Remington's Pharmaceutical Sciences" 17th ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and Encyclopedia of Pharmaceutical Technology explained in.
Farmasötik olarak kabul edilebilir solvatlar örnegin hidratlardir. Pharmaceutically acceptable solvates are, for example, hydrates.
Mevcut bulusun, uygulanabilirlik kapsamina dair diger detaylar, bu noktadan sonra verilen detayli açiklamadan belirgin hale gelecektir. Ancak, bulusun anlami ve kapsami içerisindeki birçok degisiklik ve modifikasyon, teknikte uzman kisilere bu açiklama sayesinde belirgin hale geleceginden, bulusun tercih edilen düzenlemelerini belirtmelerine ragmen detayli açiklama ve spesifik örneklerin, yalnizca tanimlama yoluyla verildigi anlasilmalidir. Çizimlerin Kisa Açiklamasi Mevcut bulus, asagida verilen detayli açiklama sayesinde ve daha bütünlüklü sekilde anlasilir hale gelecektir ve böylelikle, yalnizca tanimlama yoluyla verilen ekli çizimler, mevcut bulusu kisitlayici degildir ve burada: Sekil 1 bir ilaç dagitim cihazinin sematik bir boyuna kesitidir. Further details of the scope of applicability of the present invention are hereinafter will become apparent from the detailed description given. However, the meaning and scope of the invention Many changes and modifications within this disclosure to those skilled in the art preferred embodiments of the invention, as it will become apparent through detailed description and specific examples, although they indicate must be understood through Brief Description of Drawings The present invention has been made more fully by virtue of the detailed description given below. comprehensible so that the attached drawings, which are given by way of description only, The present invention is non-limiting and is here: Figure 1 is a schematic longitudinal section of a drug delivery device.
Tercih Edilen Düzenlemelerin Detayli Açiklamasi Sekil 1, bir ilaç dagitim cihazinin (1) sematik bir boyuna kesitidir. Ilaç dagitim cihazi (1), içerisinde bir ilacin muhafaza edilmesine yönelik bir bosluk (3) tanimlayan silindirik bir konteyner (2) içerir. Bir nozül (4), konteynerin (2) bir distal ucunda düzenlenir, burada nozül (4), bosluk (3) ile akiskan madde iletisimi içindedir. Nozül (4), içi bos bir enjeksiyon ignesi olarak düzenlenebilir. Bosluk (3), ilacin nozül (4) içinden çikarilmasina yönelik, konteyner (2) içinde eksenel olarak hareket ettirilebilen silindirik bir tapa (5) yoluyla proksimal olarak sinirlanir. Bir tapa levhasi (6), tapaya (5) proksimal olarak bitistirilir. Bir lineer aktör (7), tapa levhasi (6) ile bir kenetlenme düzenlemesi (8) arasinda hareket etmek amaciyla, tapa levhasindan (6) proksimal olarak düzenlenir. Detailed Description of Preferred Embodiments Figure 1 is a schematic longitudinal section of a drug delivery device (1). drug delivery device (1), a cylindrical shape defining a cavity (3) for containing a drug. contains the container (2). A nozzle (4) is arranged at a distal end of the container (2), where the nozzle (4) is in communication with the cavity (3) with the fluid substance. The nozzle (4) is a hollow can be arranged as an injection needle. The cavity (3) is through the nozzle (4) of the drug. cylindrical, which can be moved axially inside the container (2) for removal it is limited proximally by a plug (5). A plug plate (6) proximal to the plug (5) is terminated. A linear actor (7), an interlocking arrangement (8) with the plug plate (6) arranged proximally from the plug plate (6) in order to move between
Kenetlenme düzenlemesi (8), etkin olarak konteynere (2) kenetlenecek sekilde düzenlenir. Kenetlenme düzenlemesi (8), bir distal yöne (D) dogru koniklesen birkaç kama blogu (8.1) ve bir proksimal yöne (P) dogru koniklesen bir konik iç halka (8.2) içerir, burada kama bloklari (8.1 ), iç halka (8.2) etrafinda es merkezli olarak düzenlenir. The docking arrangement (8) is such that it is effectively docked with the container (2). is arranged. The clamping arrangement (8) is composed of several tapering towards a distal direction (D). wedge block (8.1) and a conical inner ring (8.2) tapering to a proximal direction (P) The wedge blocks (8.1) are arranged concentrically around the inner ring (8.2).
Iç halka (8.2), örnegin, iç halkadan (8.2) ve kama bloklarindan (8.1) proksimal olarak düzenlenen silindirik bir proksimal levhaya (8.3) bitistirilir. Proksimal levha (8.3), konteyner (2) içinde düzenlenir. Kenetlenme düzenlemesi (8), bir birinci sürtünme kuvveti ile konteyner (2) duvarina sürtünmeli olarak baglidir. Kenetlenme düzenlemesi (8) ile konteyner (2) duvari arasindaki birinci sürtünme kuvveti, tapa (5) ile konteyner (2) duvari arasindaki bir sürtünme kuvvetinden büyük ölçüde daha düsüktür. Her bir kama blogu (8.1), nispeten güçsüz bir sikistirma yayi olarak düzenlenen ilgili bir yay (8.4) yoluyla proksimal levhaya (8.3) karsi distal yönde (D) egilimlidir. Yaylar (8.4), proksimal levhaya (8.3) bitistirilebilir ve kama blogu (8.1) ve iç halkanin (8.2) azaltilmasina yönelik islev görür. Inner ring (8.2) eg proximally from inner ring (8.2) and wedge blocks (8.1) it is attached to a cylindrical proximal plate (8.3) arranged. Proximal plate (8.3), it is arranged in the container (2). The clamping arrangement (8), a first friction It is frictionally attached to the container (2) wall by force. docking arrangement The first frictional force between the (8) and the container (2) wall is the plug (5) and the container (2). (2) is substantially less than a frictional force between the wall. Each wedge block (8.1), a related spring arranged as a relatively weak compression spring It is inclined in the distal direction (D) against the proximal plate (8.3) through (8.4). Springs (8.4), It can be attached to the proximal plate (8.3) and is attached to the wedge block (8.1) and inner ring (8.2). functions to reduce it.
Lineer aktöre (7) yönelik bir enerji tedarik kablosu (9), konteynerin (2) proksimal ucu içinden ve proksimal levha (8.3) ve iç halka (8.2) içinden ilerletilir. Kablo (9) ayni zamanda, lineer aktörün (7) hareketini kontrol etme islevi görür. Alternatif olarak, lineer aktöre (7) güç tedarik etmek üzere, kenetlenme düzenlemesi (8) içinde bir pil saglanir. An energy supply cable (9) for the linear actor (7), the proximal end of the container (2) and through the proximal plate (8.3) and the inner ring (8.2). Cable (9) in kind At the same time, it functions to control the motion of the linear actor (7). Alternatively, linear A battery is provided in the docking arrangement 8 to power the actor 7 .
Bu durumda, kablo (9) yalnizca, lineer aktöre (7) yönelik kontrol sinyalleri saglamak için kullanilir. Bir diger örnek düzenlemede, kontrol sinyali, lineer aktöre kablosuz olarak gönderilir, bu durumda bu, bir kablosuz alici-verici içerir. Böylelikle, bir kablo gerekli Iç halkanin (8.2), kama bloklarina (8.1) göre, örnegin lineer aktörün (7) tahrik edilmesi yoluyla proksimal yönde (P) hareket ettirilmesi halinde, kama bloklari (8.1) ve iç halka (8.2), konteynerin (2) duvarina dogru zorlanir, böylelikle konteyner (2) duvari ile ilgili olarak ikinci bir sürtünme kuvvetine sahip olacak sekilde kenetlenme düzenlemesini (8) açar, burada ikinci sürtünme kuvveti, tapa (5) ile konteyner (2) duvari arasindaki sürtünme kuvvetinden büyük ölçüde daha büyüktür. Lineer aktörün (7) proksimal ucu böylelikle, konteyner (2) Içinde hareketsiz hale gelir, bu sekilde aktörün (7) daha fazla genislemesi, tapanin (5) konteyner duvarindan kurtulmasina yol açar, bu, aktörün (7) genisleme miktarina bagli olarak, ilacin boslugu (3) birakarak nozül (4) içinden çikmasi ile sonuçlanir. Örnek niteligindeki bir düzenlemede, distal yöne (D) dogru koniklesen bir konik iç yüzeye sahip bir halka, kama bloklari (8.1) yerine düzenlenebilir. Ancak bu durumda, halka materyalinin, sürtünme kuvvetlerinin iliskisini saglayacak sekilde elastik olmasi gerekir. In this case, the cable (9) is only used to provide control signals to the linear actor (7). used. In another exemplary embodiment, the control signal is wirelessly transmitted to the linear actor. sent, in which case this includes a wireless transceiver. Thus, a cable is required Actuation of the inner ring (8.2) relative to the wedge blocks (8.1), for example the linear actuator (7) key blocks (8.1) and inner ring (8.2) is forced against the wall of the container (2) so that the corresponding wall of the container (2) the clamping arrangement (8) so that it has a second friction force as opens, where the second frictional force between the plug (5) and the container (2) wall is substantially greater than the friction force. Proximal end of linear actor (7) thus, the container (2) becomes immobile in it, so that more of the actor (7) enlargement causes the plug (5) to be released from the container wall, which causes the actor (7) depending on the amount of expansion, the drug exits through the nozzle (4), leaving the cavity (3). results in. In an exemplary embodiment, a cone tapering towards the distal direction (D) a ring with a conical inner surface can be arranged in place of the wedge blocks (8.1). However, this In this case, the ring material is elastic enough to ensure the relationship of frictional forces. must be.
Lineer aktör (7), bir solenoid veya bir aks ve bir somuna sahip bir elektrik motoru içerebilir. The linear actuator (7) is a solenoid or an electric motor with an axle and a nut. may contain.
Lineer aktör (7), tahrik edildigi sekle bagli olarak genisleyecek ve daralacak sekilde düzenlenebilir. The linear actor (7) expands and contracts depending on the way it is driven. editable.
Tapa levhasi (6), tapaya (5) bitistirilir, bu, lineer aktörün (7) daralmasi üzerine, lineer aktörün (7) distal ucunun, tapa (5) ile konteyner (2) arasindaki sürtünme yoluyla konteyner duvari içinde hareketsiz hale gelecegi, bu sirada lineer aktörün (7) proksimal ucunun, iç halkayi (8.2) kama bloklarindan (8.1) uzaga çekerek, böylelikle kenetlenme düzenlemesini (8) serbest birakacagi sekildedir. Tapanin (5) konteyner (2) içindeki sürtünme kuvveti, kenetlenme düzenlemesinin (8) serbest birakilmasi için gerekli olan kuvvetin yani sira, lineer aktörün (7) daralmasi üzerine tapaya (5) dogni çekildiginde kama bloklarinin (8.1) konteyner (2) içindeki sürtünme kuvvetinden büyük ölçüde daha büyüktür. The plug plate (6) is attached to the plug (5), which, upon contraction of the linear actor (7), the distal end of the actor (7) through friction between the plug (5) and the container (2). that it will become immobile within the container wall, while the linear actor (7) is proximal end, pulling the inner ring (8.2) away from the wedge blocks (8.1), thus locking arrangement (8) is released. The plug (5) inside the container (2) the frictional force required to release the clamping arrangement (8) as well as the force, when the rivet is pulled into the plug (5) upon the contraction of the linear actor (7) The wedge blocks (8.1) are substantially greater than the friction force inside the container (2). is big.
Tapa (5) ile tapa levhasi (6) arasindaki baglanti, lineer aktör (7) ve kenetlenme düzenlemesini (8) yeniden kullanilabilecek hale getirmek amaciyla, örnegin geçmeli kenetlenme yoluyla serbest birakilabilecek sekildedir. Lineer aktör (7) ve kenetlenme düzenlemesini (8) yeniden kullanmak amaciyla, bunlarin konteynerin (2) proksimal ucunun (P) disina çekilmesi zorunludur. Bu amaca yönelik olarak, kama bloklari (8.1), yaylarin (8.4) meyline karsi proksimal levhaya (8.3) dogru nötr bir pozisyona hareket ettirilir, bu sekilde bunlar, proksimal levha (8.3) ve Iç halka (8.2), proksimal yönde (P) çekildiklerinde, konteyner (2) duvarini zorlamazlar. Kama bloklarinin (8.1) bu sekilde konumlandirilmasi, disaridan düzenlenen veya konteyner (2) üzerinde düzenlenebilir bir halka miknatis (gösterilmemistir) veya iç halka (8.2) üzerinde veya proksimal levha (8.3) üzerinde düzenlenen bir solenoid (gösterilmemistir) yoluyla elde edilebilir. Veya kama bloklari (8.1), konteynerin (2) proksimal ucu içinden yerlestirilen mekanik veya manyetik araçlar yoluyla nötr pozisyona hareket ettirilebilir. Örnek niteligindeki bir düzenlemede, lineer aktör (7) ve kenetlenme düzenlemesi (8), yeniden kullanilabilir degildir veya atilabilecek formdadir. Bu durumda lineer aktör (7), direkt olarak tapaya (5) bitistirilebilir, bu sekilde tapa levhasi (6) gerekli olmaz. The connection between the plug (5) and the plug plate (6), the linear actor (7) and the clamping in order to make the arrangement (8) reusable, e.g. it can be released by clamping. Linear actor (7) and docking To reuse the arrangement (8) they must be placed on the proximal part of the container (2). The tip (P) must be pulled out. For this purpose, wedge blocks (8.1), movement to a neutral position towards the proximal plate (8.3) against the inclination of the springs (8.4) the proximal plate (8.3) and the Inner ring (8.2) in the proximal direction (P). when they are pulled, they do not force the container (2) wall. In this way, the wedge blocks (8.1) its positioning can be arranged externally or on the container (2) on a ring magnet (not shown) or on the inner ring (8.2) or on the proximal plate It can be obtained via a solenoid (not shown) arranged on (8.3). Or wedge blocks (8.1) are mechanical or It can be moved to the neutral position by magnetic means. In an exemplary embodiment, the linear actor (7) and the docking arrangement (8), it is not reusable or in disposable form. In this case, the linear actor (7), it can be attached directly to the plug (5) so that the plug plate (6) is not required.
Ilaç dagitim cihazi (1), proteinler, asi maddeleri, kompleks karbonhidratlar veya büyüme hormonlari gibi sivi ilaçlarin dagitilmasina yönelik uygulanabilir. The drug delivery device (1) contains proteins, acids, complex carbohydrates or It can be applied for the distribution of liquid drugs such as growth hormones.
Tapanin toplam ayar araliginin, lineer aktör (7) ve kenetlenme düzenlemesinin (8) açiklanan düzenlemesi yoluyla istege göre bir sayida küçük asamalara bölünebilmesi nedeniyle, lineer aktör (7), küçük bir ayar araligina sahip yüksek hassasiyetli bir lineer aktör olabilir. The total adjustment range of the plug, linear actuator (7) and clamping arrangement (8) can be arbitrarily divided into a number of smaller stages through the arrangement described Because of this, the linear actor (7) is a high-precision linear actuator with a small adjustment range. Could be an actor.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12173959 | 2012-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201902137T4 true TR201902137T4 (en) | 2019-03-21 |
Family
ID=48745910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/02137T TR201902137T4 (en) | 2012-06-27 | 2013-06-25 | Plug arrangement for a drug delivery device. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9737658B2 (en) |
| EP (1) | EP2866865B1 (en) |
| JP (1) | JP6263174B2 (en) |
| CN (1) | CN104334218B (en) |
| DK (1) | DK2866865T3 (en) |
| HK (1) | HK1205703A1 (en) |
| TR (1) | TR201902137T4 (en) |
| WO (1) | WO2014001308A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108888826A (en) * | 2018-06-11 | 2018-11-27 | 杭州光启医疗科技发展有限公司 | Administration pump with successive administration function |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375638B2 (en) * | 1999-02-12 | 2002-04-23 | Medtronic Minimed, Inc. | Incremental motion pump mechanisms powered by shape memory alloy wire or the like |
| US20050171476A1 (en) * | 2002-05-24 | 2005-08-04 | Judson Jared A. | Medication injecting apparatus with fluid container piston-engaging drive member having internal hollow for accommodating drive member shifting mechanism |
| US6723072B2 (en) | 2002-06-06 | 2004-04-20 | Insulet Corporation | Plunger assembly for patient infusion device |
| US7993108B2 (en) * | 2002-10-09 | 2011-08-09 | Abbott Diabetes Care Inc. | Variable volume, shape memory actuated insulin dispensing pump |
| JP2007127086A (en) * | 2005-11-04 | 2007-05-24 | Terumo Corp | Pump |
| GB0607401D0 (en) | 2006-04-12 | 2006-05-24 | Glaxosmithkline Biolog Sa | Novel device |
| EP2167171B1 (en) | 2007-06-04 | 2017-08-02 | Becton, Dickinson and Company | Positive displacement stopper for a pre-filled syringe |
| GB0805521D0 (en) * | 2008-03-27 | 2008-04-30 | The Technology Partnership Plc | Dispensing system |
| US9555194B2 (en) | 2009-03-31 | 2017-01-31 | Sanofi-Aventis Deutschalnd Gmbh | Drug delivery device |
| US8881954B2 (en) * | 2010-08-30 | 2014-11-11 | Sanofi-Aventis Deutschland Gmbh | Actuator for dispensing fluid from a cartridge |
| US8535268B2 (en) * | 2010-12-22 | 2013-09-17 | Alcon Research, Ltd. | Device for at least one of injection or aspiration |
-
2013
- 2013-06-25 EP EP13733252.4A patent/EP2866865B1/en active Active
- 2013-06-25 WO PCT/EP2013/063235 patent/WO2014001308A1/en active Application Filing
- 2013-06-25 US US14/405,989 patent/US9737658B2/en not_active Expired - Fee Related
- 2013-06-25 CN CN201380030079.6A patent/CN104334218B/en not_active Expired - Fee Related
- 2013-06-25 JP JP2015519048A patent/JP6263174B2/en not_active Expired - Fee Related
- 2013-06-25 TR TR2019/02137T patent/TR201902137T4/en unknown
- 2013-06-25 DK DK13733252.4T patent/DK2866865T3/en active
-
2015
- 2015-07-03 HK HK15106352.2A patent/HK1205703A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150148745A1 (en) | 2015-05-28 |
| US9737658B2 (en) | 2017-08-22 |
| JP2015525581A (en) | 2015-09-07 |
| CN104334218B (en) | 2017-06-20 |
| EP2866865B1 (en) | 2018-11-14 |
| EP2866865A1 (en) | 2015-05-06 |
| CN104334218A (en) | 2015-02-04 |
| HK1205703A1 (en) | 2015-12-24 |
| JP6263174B2 (en) | 2018-01-17 |
| WO2014001308A1 (en) | 2014-01-03 |
| DK2866865T3 (en) | 2019-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107405453B (en) | Sensor assembly for an injection device | |
| CN105682707B (en) | There are two the medicament delivery devices of driving spring for tool | |
| CN110420368B (en) | Injection device | |
| CN106470718B (en) | Medicament delivery device with activation mechanism | |
| CN105960254B (en) | Medicament delivery device | |
| CN105658267B (en) | Driving mechanism for contact pin assembly | |
| TR201808673T4 (en) | The drive mechanism and the drug delivery device for a drug delivery device. | |
| US9364614B2 (en) | Drug delivery device | |
| JP6711836B2 (en) | Drug delivery device | |
| CN107405458B (en) | Medicament delivery device and method of assembling a medicament delivery device | |
| JP2020044374A (en) | Activating mechanism for medicament delivery device, and medicament delivery device | |
| JP6702975B2 (en) | Needle interface | |
| CN106456892A (en) | Activating mechanism for a medicament delivery device and medicament delivery device | |
| TW201302257A (en) | Drug delivery device and cartridge holder for a drug delivery device | |
| CN106102805B (en) | Assembly for a drug delivery device | |
| CN105555338A (en) | Drive unit for a drug delivery device | |
| CN105188809A (en) | Assembly for a drug delivery device comprising a feedback feature | |
| CN105377336B (en) | Perfusion for medical device starts tectosome and starts the medicine delivery device of tectosome including perfusion | |
| KR102168900B1 (en) | Drug delivery device | |
| TR201902137T4 (en) | Plug arrangement for a drug delivery device. | |
| JP2015511157A (en) | Spring assembly for drug delivery device | |
| JP2017504423A (en) | Drug delivery device | |
| CN105813670B (en) | Housing for a drug delivery device | |
| JP2018527109A (en) | Drug delivery device | |
| CN104582769B (en) | Lid and medicine delivery device for medicine delivery device |